Lucentis Prefilled Syringe

Buy Lucentis Prefilled Syringe 10mg/ml 0.05ml online

Basic Properties

Buy Lucentis Prefilled Syringe 10mg/ml 0.05ml online

Lucentis is an ophthalmic drug from NOVARTIS PHARMA, AG that has a beneficial effect on the eyes. It helps to reduce the likelihood of decreased visual acuity due to the cessation of the growth of new vessels in the retina. The active substance is ranibizumab, a fragment of a humanized antibody to endothelial growth factor A (VEGF-A), and is expressed by a recombinant strain of Escherichia coli. The composition of Lucentis 10 mg/ml 0.5 mg (0.05) ml also includes the following excipients α, α-trehalose dihydrate – 100 mg / 23 mg, L-histidine hydrochloride monohydrate – 1.66 mg / 382 μg, L-histidine – 320 μg / 74 μg, polysorbate 20 – 100 μg / 23 μg, water d / i – up to 1 ml / up to 0.23 ml.

One package of Lucentis includes 1 prefilled syringe with the injectable solution for intraocular administration: transparent or slightly opalescent, colorless suspension.

You can buy Lucentis prefilled syringe 10mg/ml 0.05ml on Mountain View Pharma

Indications

Lucentis ranibizumab injection is indicated for the treatment of neovascular (wet) age-related macular degeneration in adults; treatment of decreased visual acuity associated with diabetic macular edema following retinal vein occlusion (RVO) as monotherapy or in combination with laser coagulation in patients who have previously undergone laser coagulation,  diabetic retinopathy, etc.

Dosage of Lucentis

Lucentis ranibizumab injection can be applied only as an injection into the vitreous body.

The recommended dose for the injection is 0.5 mg (monthly dosing) once a month.

The first three injections are performed at a frequency of 1 time/month sequentially for 3 months. Treatment is stopped (stabilization phase), and visual acuity is checked regularly (at least 1 time/month). With a decrease in visual acuity by more than 5 letters on the ETDRS visual acuity scale (1 line according to the Snellen table), Lucentis treatment is resumed.

An interval of at least 1 month should be observed between the introduction of two doses.

Rules of Administration

Before the Lucentis injection procedure, it is necessary to carry out appropriate disinfection of the eyelid skin and the area around the eyes, anesthesia of the conjunctiva, and therapy with a wide range of antimicrobial drugs.

Antimicrobial drugs should be instilled into the conjunctival sac 3 times a day for 3 days before and after drug administration.

Lucentis should be inserted into the vitreous body 3.5-4 mm posterior to the limbus, avoiding the horizontal meridian and guiding the needle towards the center of the eyeball. The volume of the injected drug is 0.05 ml.

The next injection of the drug is carried out in the other half of the sclera.

Since intraocular pressure (IOP) may increase within 60 minutes following intravitreal injection with Lucentis, IOP, patients should be monitored for the perfusion of the optic nerve head.

In one session, the introduction of Lucentis is carried out only in one eye.

Side Effects

Infections and invasions: very often – nasopharyngitis; often – the flu.

Hematopoietic system: often – anemia.

From the side of the psyche: often – anxiety.

Central nervous system: very often – headache; sometimes a stroke.

From the side of the organ of vision: very often – intraocular inflammation, inflammation of the vitreous humor, detachment of the vitreous humor, retinal hemorrhages, visual disturbances, eye pain, opacities in the vitreous humor, increased intraocular pressure, conjunctival hemorrhages, eye irritation, foreign body sensation in the eye, lacrimation, blepharitis, dry eye syndrome, eye redness, itchy eyes; often – degenerative changes in the retina, retinal damage, retinal detachment, retinal ruptures, retinal pigment epithelium detachment, pigment epithelium rupture, decreased visual acuity, vitreous hemorrhage, vitreous lesion, uveitis, iritis, iridocyclitis, cataract, subcapsular cataract lens capsules, punctate keratitis, corneal erosion, cellular opalescence in the anterior chamber of the eye, blurred vision, hemorrhage at the injection site, ocular hemorrhages, conjunctivitis, allergic conjunctivitis, eye discharge, photopsia, photophobia, discomfort in the eyes, eyelid swelling , conjunctival hyperemia; sometimes – blindness, endophthalmitis, hypopyon, hyphema, keratopathy, iris adhesions, corneal deposits, corneal edema, corneal striae, pain and irritation at the injection site, atypical sensations in the eye and irritation of the eyelids.

From the respiratory system: often – cough.

The digestive system: often – nausea.

Allergic reactions: often – rash, hives, itching.

Musculoskeletal system: very often – arthralgia.

Contraindications

• Confirmed or suspected eye infections or infections of the periocular localization;
• intraocular inflammation;
• children and adolescents up to 18 years old;
• pregnancy; lactation period (breastfeeding);
• hypersensitivity to ranibizumab.

It should be used with caution in patients with a history of hypersensitivity reactions in the presence of risk factors for stroke. In such cases, the use is possible only after a careful assessment of the risk/benefit ratio.

With the injection of endothelial growth factor A (VEGF-A) inhibitors into the vitreous body, arterial thromboembolic complications may develop.

The risk of developing a stroke may be higher if patients have risk factors, including a previous stroke or a history of transient cerebrovascular accident.

Where to Buy Lucentis Ranibizumab Prefilled Syringe?

If you are looking to buy Lucentis prefilled 0.5 mg syringe for an intravitreal injection to improve a decrease in vision due to diabetic macular edema (DME), patients with neovascular (AMD) wet age-related macular degeneration, myopic choroidal neovascularization (MCNV),  diabetic retinopathy, myopic choroidal neovascularization, welcome to Mountain View Pharma